Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of high-dose methotrexate efficacy and adverse reactions in acute lymphoblastic leukemia using pharmacogenomics and metabolomics
ChiCTR1800015307Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in acute lymphoblastic leukemia (ALL), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Genotype. Started Jan 2016; status: recruiting.
02
Drugs
methotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR1800015307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015307.